Skip to content

Demonstration Project for the Application of Human KRAS/BRAF/PIK3CA Gene Mutation Detection Kit in Screening Cetuximab Indications for Colorectal Cancer

Demonstration Project for the Application of Human KRAS/BRAF/PIK3CA Gene Mutation Detection Kit in Screening Cetuximab Indications for Colorectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126490
Enrollment
Unknown
Registered
2026-06-10
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Observation group:None

Sponsors

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age =18 years, male or female; 2.Patients diagnosed with colorectal adenocarcinoma by postoperative pathology following puncture, biopsy/resection at our hospital; 3.Having sufficient pathological tissue samples with tumor cellularity =10%.

Exclusion criteria

Exclusion criteria: 1.Patients with synchronous multiple primary cancers or a history of previous malignant tumors; 2.Patients with hematologic or lymphatic malignancies; 3.Patients without a detailed histopathological diagnosis report; 4.Insufficient or poor-quality pathological tissue samples (failed quality control).

Design outcomes

Primary

MeasureTime frame
Precision ;Sensitivity;Specificity;Accuracy;

Countries

China

Contacts

Public ContactZebing Liu

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

18719@renji.com+86 21 6838 3349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026